It is well established that metabolism plays a major role in modulating the immune system, with mounting clinical evidence indicating that tumor-induced metabolic dysregulation influences treatment outcomes to anti-PD-1 therapy (15, 16, 17, 18, 19). Here, PDCD1 is linked to neoplasm.